The Justice Department announced an executive action to ease federal restrictions on state-licensed medical marijuana by reclassifying FDA-approved and state-licensed cannabis from Schedule I to Schedule III, while initiating an expedited hearing process to finalize the rescheduling.

Acting Attorney General Todd Blanche stressed that the move does not legalize marijuana or endorse recreational use, but it advances greater research oversight and access for medical treatment options.

The action launches a broader review of marijuana scheduling with a hearing planned for late June to consider the change and its implications.

Experts and industry groups warn about safety and impairment standards, noting potential testing blind spots and urging careful implementation, including possible use of hair testing data in federal records.

Data highlights racial disparities in enforcement, with higher arrest and conviction rates for Black Americans, and concerns that tax and licensing benefits could disproportionately aid white-owned businesses and widen industry disparities.

The article invites CSP members to access CSP Daily News content, signaling ongoing industry coverage.

Individual cases, such as Hector Ruben McGurk, who faces life without parole for marijuana transport and money laundering, illustrate limits of the order in addressing harsh sentences.

Ongoing concerns about long-term marijuana use affecting youth brain development and potential impacts on male fertility are part of the policy discussion.

Political opposition remains among some Republicans, who argue against loosening restrictions, even as the move aligns with broader efforts to address drug policy and public health priorities.

Trump-era framing of the issue is cited, with critics noting ongoing political contention over the rescheduling and its implications.

Reactions are mixed: advocates view the step as historic for medical recognition and research access, while critics warn it could amount to a tax break for industry players and send misleading messages about harms.

Opponents such as Smart Approaches to Marijuana argue the change benefits industry players and risks signaling leniency on marijuana harms.